Trial intelligence / Profile preview

BEGIN Flex T1

2009-012923-27Phase 3Completed

Sponsor
Novo Nordisk
Start
Nov 2009
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, open-label trial of insulin degludec in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Nov 2009; status: completed.

02

Drugs

insulin degludec
03

Conditions

diabetes mellitus type 1 (T1D)

Beyond the preview

Go deeper on 2009-012923-27.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-012923-27.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call